Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.
Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials.
Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.
This podcast is for you if:
- You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership
- You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness
- You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny
- You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources
What you will learn:
CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma.
Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.
New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.
Next Steps:
Visit the Website: https://smartbiotechscientist.com
Email us: hello@bruehlmann-consulting.com
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 2
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position.
In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade building a company on licensing proprietary microbial technology rather than selling fermentation capacity, he brings a distinctive vantage point on where the CDMO industry is headed and what it will take to stay relevant.
Here are some of the topics discussed:
- The need for innovation to stay competitive against lower-cost regions, and why capacity-focused business models are running out of road (03:08)
- How continuous manufacturing creates a competitive edge for CDMOs operating in high-cost regions (05:49)
- Practical advice for piloting continuous processing, building partnerships, and taking calculated risks before competitors do (06:36)
- The parallel universe of batch and continuous manufacturing, and how this duality will shape the industry over the next decade (08:24)
- What scientists need to know before spinning out a technology company: customer focus, cash discipline, and why the team is everything (09:49)
- Big pharma's return to in-house manufacturing and vertical supply chain integration, and why this creates opportunity for innovation-focused partners (12:12)
Smart insight: Technology excellence is necessary but not sufficient. Juergen's closing word was simply "don't be afraid" and it carried weight precisely because it was not a platitude. The companies that will matter in ten years are those that start the hard work of innovation now, before the window closes.
If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:
- Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
- Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
- Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
- Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
- Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
- Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos
Connect with Juergen Mairhofer:
LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b
enGenes Biotech GmbH website: www.engenes.cc
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here